Though it was not demonstrated if the oncogenic property is related to DDI2′s protease activity or an alternative, such as serving as an ubiquitin receptor protein [35], it is possible that a DDI2 protease inhibitor may have anti-tumor activity independent of the NRF1-mediated bounce-back response. The gene discussed is NRF1; the disease is neoplasm.